Rosemont Pharmaceuticals Limited is dedicated to improving the health and wellbeing of people through the development, manufacturing and marketing of high quality generic oral liquid medicines. We are leading specialists in the supply of liquid medicines for people who have swallowing difficulties, or for those who need a precise measured dose unavailable in a solid tablet or capsule.
Our facilities are inspected by both the UK and US regulatory authorities and through adherence to Good Manufacturing Practice (GMP) and international quality control standards; we ensure that all our medicines can be used with a high degree of confidence. Through significant research and development, we manufacture a range of more than 160 different liquid formulations covering 11 BNF categories. Acquired by Perrigo Company plc in 2013, we have 49 years’ experience in supplying oral liquid medicines to customers who see Rosemont as ‘The Source of Liquid Solutions’.
Rosemont’s commitment is to the promotion of best practice when administering medication; through continuing support of healthcare professionals and provision of free educational training meetings and materials to assist them in delivering the best possible care for their patients.

Proveca is a UK based pharmaceutical company specialising in the development and licensing of off-patent medicines for children throughout Europe www.proveca.co.uk. Around 20% of the EU population (100m) is under 18 years of age, yet the majority of medicines used in children have not been formulated for, or evaluated in children. Marketing approval (product licence) is gained via a Paediatric Use Marketing Authorisation (PUMA), a regulatory route developed specifically for licensing off-patent medicines for children in Europe.
Proveca was founded by Dr Helen Shaw, a physician with over 25 years’ experience in the pharmaceutical industry and Dr Simon Bryson, a pharmaceutical professional whose PhD is in Paediatric Medication Adherence. Proveca’s first PUMA (Sialanar, paediatric licensed oral glycopyrronium bromide) was granted in September 2016 and its pipeline contains medicines for heart failure and epilepsy.
For more information contact:
Robert Holmes
Email: robertholmes@proveca.co.uk
Tel: 07931 684124

Fresenius Kabi is the leader in infusion therapy and clinical nutrition in Europe. It is focused on the therapy and care of critically and chronically ill patients in both the hospital and home environment. The company develops, manufactures and markets products that offer efficient clinical outcomes combined with a commitment to quality and patient safety.
With a corporate philosophy of “Caring for Life” the company’s goal is to improve the patient’s quality of life. This means that we continuously strive to develop our specialist skills in the fields of nutrition, infusion therapy, oncology and homecare. In doing so we provide innovative solutions to meet the highest standards of patient care.
The company offers a wide range of products and services including;
- Infusion Therapy Solutions
- IV Drugs
- Enteral and Parenteral Nutrition
- Specials Service offering ready to use IV drugs, infusion solutions and parenteral nutrition presentations
- Medical Devices, and Technical Services
- Homecare Service via Calea UK Ltd, part of the Fresenius Kabi Group.
For more information contact:
Karen Rosevear
Email: karen.rosevear@fresenius-kabi.com
Tel: +44 (0)1928 533732
Supported by the European Association of Hospital Pharmacists (EAHP)
see also
23rd Congress of the EAHP – 21 – 23 March 2018 in Gothenburg, Sweden
EAHP is pleased to invite you to the 23rd Congress of the EAHP 21st- 23rd March 2018 with the theme of “Hospital pharmacists – Show us what you can do!”. The scientific program is well advanced and is relevant for you as a hospital pharmacist dealing with the challenges of economic restrictions and increased demands. This congress provides an opportunity to demonstrate what hospital pharmacists have achieved, to provide inspiration for future development and to energise us for the road ahead. This opportunity to showcase the benefits facilitated by hospital pharmacists will influence decision makers, multidisciplinary team members and patients to demand hospital pharmacists’ full engagement in the medication process.
EAHP’s annual congress is the largest congress for hospital pharmacy in Europe and is attended by pharmacists from all over the world. This Congress continues to provide you with an exceptional opportunity to meet, network and share expertise and best practice with colleagues while keeping up to date with the latest developments in hospital pharmacy.
Important dates:
– 15 October 2017: Deadline for abstract and “Good Practice Initiative” submission
– Before 1 December 2017: Registration – early rate
– BEGINNING 1 December 2017: Registration- 2nd rate
– BEGINNING 1 February 2018: Registration – 3rd rate and on-site